EphA2 immunoconjugate

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications

Volumn , Issue , 2013, Pages 241-253

  Xiao, Zhan ^a   Jackson, Dowdy ^b   Tice, David A ^a  

^a MEDIMMUNE   (United States)

^b Agensys Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988912512     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5456-4_14     Document Type: Chapter

References (59)

1. Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475-486
2. Murai KK, Pasquale EB (2003) 'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci 116:2823-2832
3. Beckmann MP, Cerretti DP, Baum P et al (1994) Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. EMBO J 13:3757-3762
4. Davis S, Gale NW, Aldrich TH et al (1994) Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266:816-819
5. Egea J, Nissen UV, Dufour A et al (2005) Regulation of EphA4 kinase activity is required for a subset of axon guidance decisions suggesting a key role for receptor clustering in Eph function. Neuron 47:515-528
6. Vearing CJ, Lackmann M (2005) Eph receptor signalling: dimerisation just isn't enough. Growth Factors 23:67-76
7. Himanen JP, Chumley MJ, Lackmann M et al (2004) Repelling class discrimination: ephrin- A5 binds to and activates EphB2 receptor signaling. Nat Neurosci 7:501-509
8. Gale NW, Yancopoulos GD (1997) Ephrins and their receptors: a repulsive topic? Cell Tissue Res 290:227-241
9. Flanagan JG, Vanderhaeghen P (1998) The ephrins and Eph receptors in neural development. Annu Rev Neurosci 21:309-345
10. Hafner C, Schmitz G, Meyer S et al (2004) Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50:490-499
11. Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38-52
12. Zisch AH, Pasquale EB (1997) The Eph family: a multitude of receptors that mediate cell recognition signals. Cell Tissue Res 290:217-226
13. Huusko P, Ponciano-Jackson D, Wolf M et al (2004) Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36:979-983
14. Kittles RA, Baffoe-Bonnie AB, Moses TY et al (2006) A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43:507-511
15. Alazzouzi H, Davalos V, Kokko A et al (2005) Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65:10170-10173
16. Guo DL, Zhang J, Yuen ST et al (2006) Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 27:454-464
17. Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC, Wang B (2006) Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 66(14):7050-7058
18. Elowe S, Holland SJ, Kulkarni S, Pawson T (2001) Downregulation of the Ras-mitogen- activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin- induced neurite retraction. Mol Cell Biol 21(21):7429-7441
19. Zou JX, Wang B, Kalo MS, Zisch AH, Pasquale EB, Ruoslahti E (1999) An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci USA 96:13813-13818
20. Nakada M, Niska JA, Tran NL, McDonough WS, Berens ME (2005) EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 167:565-576
21. Kumar SR, Masood R, Spannuth WA et al (2007) The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96:1083-1091
22. Kumar SR, Scehnet JS, Ley EJ, Singh J et al (2009) Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 69(9):3736-3745
23. Noren NK, Foos G, Hauser CA, Pasquale EB (2006) The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8:815-825
24. Lindberg RA, Hunter T (1990) cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol 10:6316-6324
25. Ruiz JC, Robertson EJ (1994) The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development. Mech Dev 46:87-100
26. Chen J, Nachabah A, Scherer C et al (1996) Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion. Oncogene 12:979-988
27. Ireton RC, Chen J (2005) EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 5(3):149-157
28. Wykosky J, Debinski W (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6(12):1795-1806
29. Zeng G, Hu Z, Kinch MS et al (2003) High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163:2271-2276
30. Thaker PH, Deavers M, Celestino J et al (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10:5145-5150
31. Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA (2006) Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis 23:357-365
32. Wykosky J, Gibo DM, Stanton C, Debinski W (2005) EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3:541-551
33. Walker-Daniels J, Coffman K, Azimi M et al (1999) Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41:275-280
34. Fox BP, Kandpal RP (2004) Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318:882-892
35. Kinch MS, Moore MB, Harpole DH (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613-618
36. Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H (2003) EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103: 657-663
37. Han L, Dong Z, Qiao Y (2005) The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99:278-286
38. Hess AR, Seftor EA, Gardner LM et al (2001) Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61:3250-3255
39. Wang LF, Fokas E, Bieker M et al (2008) Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 19:151-156
40. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301-2316
41. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J (2005) A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24:7859
42. Huang F, Reeves K, Han X (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238
43. Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB (2010) Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 49(31):6687-6695
44. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS (2002) Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62(10):2840-2847
45. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S et al (2010) Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 70(1):299-308
46. Kiewlich D, Zhang J, Gross C et al (2006) Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia 8:18-30
47. Hammond SA, Lutterbuese R, Roff S et al (2007) Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res 67(8):3927-35
48. Zhuang G, Hunter S, Hwang Y, Chen J (2007) Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J Biol Chem 282(4):2683-2694
49. Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M et al (2008) A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 68(22):9367-9374
50. Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W (2008) Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 27(58):7260-75273
51. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM et al (2009) EphA2 immu- noconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 101 (17): 1193-1205
52. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM et al (2010) EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 16(9):2562-2570
53. Coffman KT, Hu M, Carles-Kinch K et al (2003) Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 63:7907-7912
54. Dall'Acqua WF, Damschroder MM, Zhang J et al (2005) Antibody humanization by framework shuffling. Methods 36(1):43-60
55. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21(7):778-84
56. Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA (1999) Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol 44(5):395-402
57. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL et al (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17(1):114-124
58. Mansouri A, Henle KJ, Nagle WA (1992) Multidrug resistance: prospects for clinical management. SAAS Bull Biochem Biotechnol 5:48-52
59. Patwardhan G, Gupta V, Huang J, Gu X, Liu YY et al (2010) Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem Pharmacol 80(1):72-79